PERtuzumab-trastuzumab plus lEetrozoLe In endocrine Sensitive breast cancer: a phase II neoAdjuvant study
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2018
Price : $35 *
At a glance
- Drugs Letrozole (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms PER-ELISA
- 18 Jul 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 18 Jul 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 05 Jun 2018 Status changed to completed as per results presented at the 54th Annual Meeting of the American Society of Clinical Oncology